Technical Analysis for KYMR - Kymera Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Stochastic Reached Oversold | Weakness | 0.00% | |
Multiple of Ten Bearish | Other | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Pocket Pivot | Bullish Swing Setup | -3.10% | |
Bollinger Band Squeeze | Range Contraction | -3.10% | |
Multiple of Ten Bullish | Other | -3.10% | |
BB Squeeze Started | Range Contraction | -3.10% | |
Fell Below 20 DMA | Bearish | -0.48% | |
Multiple of Ten Bearish | Other | -0.48% |
Alert | Time |
---|---|
Fell Below Previous Day's Low | about 13 hours ago |
Possible Inside Day | about 15 hours ago |
Down 3% | about 19 hours ago |
Down 2 % | about 19 hours ago |
Down 1% | about 19 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/02/2024
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Solid Tumors Immune System Autoimmune Disease Autoimmunity Rheumatoid Arthritis Hematologic Malignancies Atopic Dermatitis Dermatitis Hidradenitis Suppurativa
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Solid Tumors Immune System Autoimmune Disease Autoimmunity Rheumatoid Arthritis Hematologic Malignancies Atopic Dermatitis Dermatitis Hidradenitis Suppurativa
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 45.31 |
52 Week Low | 9.6 |
Average Volume | 804,158 |
200-Day Moving Average | 23.87 |
50-Day Moving Average | 35.73 |
20-Day Moving Average | 41.70 |
10-Day Moving Average | 41.58 |
Average True Range | 2.13 |
RSI (14) | 48.98 |
ADX | 39.05 |
+DI | 18.84 |
-DI | 15.88 |
Chandelier Exit (Long, 3 ATRs) | 38.91 |
Chandelier Exit (Short, 3 ATRs) | 42.77 |
Upper Bollinger Bands | 45.01 |
Lower Bollinger Band | 38.38 |
Percent B (%b) | 0.14 |
BandWidth | 15.89 |
MACD Line | 1.38 |
MACD Signal Line | 2.16 |
MACD Histogram | -0.7888 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 42.56 | ||||
Resistance 3 (R3) | 42.84 | 42.04 | 42.02 | ||
Resistance 2 (R2) | 42.04 | 41.21 | 41.90 | 41.84 | |
Resistance 1 (R1) | 40.68 | 40.71 | 40.28 | 40.40 | 41.66 |
Pivot Point | 39.88 | 39.88 | 39.68 | 39.74 | 39.88 |
Support 1 (S1) | 38.52 | 39.05 | 38.12 | 38.24 | 36.98 |
Support 2 (S2) | 37.72 | 38.55 | 37.58 | 36.80 | |
Support 3 (S3) | 36.36 | 37.72 | 36.62 | ||
Support 4 (S4) | 36.08 |